2SE Stock Overview
Sequana Medical NV develops and commercializes treatments for patients with diuretic-resistant fluid overload in liver disease, cancer, and heart failure in Belgium, Germany, France, Switzerland, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Sequana Medical NV Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.38 |
| 52 Week High | €4.69 |
| 52 Week Low | €1.35 |
| Beta | 0.83 |
| 1 Month Change | -8.61% |
| 3 Month Change | -64.43% |
| 1 Year Change | -58.68% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -85.37% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2SE | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 2.6% | -1.7% | -1.0% |
| 1Y | -58.7% | -11.2% | 2.2% |
Return vs Industry: 2SE underperformed the German Medical Equipment industry which returned -10.8% over the past year.
Return vs Market: 2SE underperformed the German Market which returned 2% over the past year.
Price Volatility
| 2SE volatility | |
|---|---|
| 2SE Average Weekly Movement | 12.4% |
| Medical Equipment Industry Average Movement | 4.5% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 2SE's share price has been volatile over the past 3 months.
Volatility Over Time: 2SE's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 62 | Ian Crosbie | www.sequanamedical.com |
Sequana Medical NV develops and commercializes treatments for patients with diuretic-resistant fluid overload in liver disease, cancer, and heart failure in Belgium, Germany, France, Switzerland, and internationally. The company products pipeline comprises alfapump system, an implantable pump system for the treatment of refractory liver ascites and malignant ascites; and Direct Sodium Removal (DSR) for the treatment of fluid overload spread across the body and heart failure. Sequana Medical NV was founded in 2006 and is headquartered in Ghent, Belgium.
Sequana Medical NV Fundamentals Summary
| 2SE fundamental statistics | |
|---|---|
| Market cap | €52.61m |
| Earnings (TTM) | -€32.56m |
| Revenue (TTM) | €712.17k |
73.9x
P/S Ratio-1.6x
P/E RatioIs 2SE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2SE income statement (TTM) | |
|---|---|
| Revenue | €712.17k |
| Cost of Revenue | €164.12k |
| Gross Profit | €548.05k |
| Other Expenses | €33.11m |
| Earnings | -€32.56m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Sep 19, 2024
| Earnings per share (EPS) | -0.91 |
| Gross Margin | 76.95% |
| Net Profit Margin | -4,572.42% |
| Debt/Equity Ratio | -86.2% |
How did 2SE perform over the long term?
See historical performance and comparison